PB1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study - Jabbour, E.; Martinelli, G.; Vignetti, M.; Kantarjian, Hagop M.; Gómez Almaguer, David; Minami, Y.; Dombret, H.; Hennessy, M.; Vorog, A.; Wang, B.; Ribera, J. M. (Wolters Kluwer Health, 2022)